CN1213746C - 免疫强化剂及其生理上可接受的盐 - Google Patents

免疫强化剂及其生理上可接受的盐 Download PDF

Info

Publication number: CN1213746C
Authority: CN; China
Prior art keywords: cell; virus; compounds; chemical compound; group
Prior art date: 1992-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CNB931144442A

Other languages

English (en)

Chinese (zh)

Other versions

CN1091005A (zh

Inventor

J·R·罗德斯

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wellcome Foundation Ltd

Original Assignee

Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-01

Filing date

1993-09-30

Publication date

2005-08-10

1992-10-01 Priority claimed from GB929220715A external-priority patent/GB9220715D0/en

1992-12-23 Priority claimed from GB929226874A external-priority patent/GB9226874D0/en

1993-09-30 Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd

1994-08-24 Publication of CN1091005A publication Critical patent/CN1091005A/zh

2005-08-10 Application granted granted Critical

2005-08-10 Publication of CN1213746C publication Critical patent/CN1213746C/zh

2013-09-30 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000003839 salts Chemical class 0.000 title claims description 44
238000011282 treatment Methods 0.000 claims abstract description 29
239000003814 drug Substances 0.000 claims abstract description 27
238000004519 manufacturing process Methods 0.000 claims abstract description 9
229910052760 oxygen Inorganic materials 0.000 claims description 12
230000035479 physiological effects, processes and functions Effects 0.000 claims description 12
239000001301 oxygen Substances 0.000 claims description 11
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
230000001900 immune effect Effects 0.000 claims description 8
239000005711 Benzoic acid Substances 0.000 claims description 4
235000010233 benzoic acid Nutrition 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
206010009944 Colon cancer Diseases 0.000 claims 1
208000029742 colonic neoplasm Diseases 0.000 claims 1
239000002955 immunomodulating agent Substances 0.000 claims 1
229940026778 other chemotherapeutics in atc Drugs 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 107
206010028980 Neoplasm Diseases 0.000 abstract description 34
239000000203 mixture Substances 0.000 abstract description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
201000010099 disease Diseases 0.000 abstract description 21
208000015181 infectious disease Diseases 0.000 abstract description 16
229940079593 drug Drugs 0.000 abstract description 4
238000011321 prophylaxis Methods 0.000 abstract description 4
230000002924 anti-infective effect Effects 0.000 abstract description 2
230000000259 anti-tumor effect Effects 0.000 abstract description 2
230000000091 immunopotentiator Effects 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 35
210000001744 T-lymphocyte Anatomy 0.000 description 31
108091007433 antigens Proteins 0.000 description 31
102000036639 antigens Human genes 0.000 description 31
239000000427 antigen Substances 0.000 description 30
238000012360 testing method Methods 0.000 description 27
241000700605 Viruses Species 0.000 description 24
238000002360 preparation method Methods 0.000 description 23
201000011510 cancer Diseases 0.000 description 20
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 20
238000000034 method Methods 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
-1 amino chemical compound Chemical class 0.000 description 16
239000002585 base Substances 0.000 description 14
229910052739 hydrogen Inorganic materials 0.000 description 14
230000036039 immunity Effects 0.000 description 14
229960001438 immunostimulant agent Drugs 0.000 description 14
239000003022 immunostimulating agent Substances 0.000 description 14
230000003308 immunostimulating effect Effects 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
239000001257 hydrogen Substances 0.000 description 13
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 12
239000007788 liquid Substances 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
230000004044 response Effects 0.000 description 12
239000003826 tablet Substances 0.000 description 12
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 11
206010061598 Immunodeficiency Diseases 0.000 description 11
208000029462 Immunodeficiency disease Diseases 0.000 description 11
230000007813 immunodeficiency Effects 0.000 description 11
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
241000725303 Human immunodeficiency virus Species 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
229910052799 carbon Inorganic materials 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000008215 water for injection Substances 0.000 description 9
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 description 8
239000002775 capsule Substances 0.000 description 8
230000006870 function Effects 0.000 description 8
230000036737 immune function Effects 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
230000007246 mechanism Effects 0.000 description 8
239000000843 powder Substances 0.000 description 8
230000009385 viral infection Effects 0.000 description 8
241000701085 Human alphaherpesvirus 3 Species 0.000 description 7
239000002253 acid Substances 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
230000000890 antigenic effect Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000002354 daily effect Effects 0.000 description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
239000002262 Schiff base Substances 0.000 description 6
208000036142 Viral infection Diseases 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000037396 body weight Effects 0.000 description 6
150000001721 carbon Chemical group 0.000 description 6
230000002950 deficient Effects 0.000 description 6
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 6
150000002431 hydrogen Chemical group 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
229930192474 thiophene Natural products 0.000 description 6
229950009795 tucaresol Drugs 0.000 description 6
241001529453 unidentified herpesvirus Species 0.000 description 6
241000701022 Cytomegalovirus Species 0.000 description 5
206010011968 Decreased immune responsiveness Diseases 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
150000004753 Schiff bases Chemical class 0.000 description 5
241000700584 Simplexvirus Species 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
239000008187 granular material Substances 0.000 description 5
229960003444 immunosuppressant agent Drugs 0.000 description 5
230000001861 immunosuppressant effect Effects 0.000 description 5
239000003018 immunosuppressive agent Substances 0.000 description 5
230000001954 sterilising effect Effects 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
229940005605 valeric acid Drugs 0.000 description 5
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
208000035473 Communicable disease Diseases 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
239000003708 ampul Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
230000007547 defect Effects 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 4
229960000961 floxuridine Drugs 0.000 description 4
150000007857 hydrazones Chemical class 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
210000001331 nose Anatomy 0.000 description 4
239000002777 nucleoside Substances 0.000 description 4
244000052769 pathogen Species 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000003380 propellant Substances 0.000 description 4
238000005507 spraying Methods 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
238000004659 sterilization and disinfection Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000001828 Gelatine Substances 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 3
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000003513 alkali Substances 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
230000034994 death Effects 0.000 description 3
230000003203 everyday effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000009545 invasion Effects 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
150000002576 ketones Chemical class 0.000 description 3
239000008101 lactose Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000000527 lymphocytic effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
150000003833 nucleoside derivatives Chemical class 0.000 description 3
239000002245 particle Substances 0.000 description 3
IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 3
201000000317 pneumocystosis Diseases 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
239000000829 suppository Substances 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
241000712461 unidentified influenza virus Species 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 2
ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
201000006082 Chickenpox Diseases 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000709661 Enterovirus Species 0.000 description 2
206010019799 Hepatitis viral Diseases 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000011931 Nucleoproteins Human genes 0.000 description 2
108010061100 Nucleoproteins Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
206010038910 Retinitis Diseases 0.000 description 2
241000710799 Rubella virus Species 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
206010043376 Tetanus Diseases 0.000 description 2
AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
206010046980 Varicella Diseases 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
229960002242 chlorocresol Drugs 0.000 description 2
KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
229940117916 cinnamic aldehyde Drugs 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001914 filtration Methods 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
230000005965 immune activity Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
239000002547 new drug Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
238000003825 pressing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000011121 sodium hydroxide Nutrition 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
125000003831 tetrazolyl group Chemical group 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
201000001862 viral hepatitis Diseases 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 description 1
BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 1
FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
KETQAJRQOHHATG-UHFFFAOYSA-N 1,2-naphthoquinone Chemical compound C1=CC=C2C(=O)C(=O)C=CC2=C1 KETQAJRQOHHATG-UHFFFAOYSA-N 0.000 description 1
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
XQSPYNMVSIKCOC-RITPCOANSA-N 4-amino-5-fluoro-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)SC1 XQSPYNMVSIKCOC-RITPCOANSA-N 0.000 description 1
AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
206010001167 Adenocarcinoma of colon Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000712891 Arenavirus Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
208000014912 Central Nervous System Infections Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010062343 Congenital infection Diseases 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
241000790917 Dioxys <bee> Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000701027 Human herpesvirus 6 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
229920001410 Microfiber Polymers 0.000 description 1
206010027906 Monocytosis Diseases 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010028470 Mycoplasma infections Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
241000233855 Orchidaceae Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
108010021119 Trichosanthin Proteins 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
MULRMTLVICSWMO-JCKUYFFHSA-N [(z)-octadec-9-enyl] (2s)-2-acetamido-5-amino-5-oxopentanoate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)[C@@H](NC(C)=O)CCC(N)=O MULRMTLVICSWMO-JCKUYFFHSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
125000002905 alkanoylamido group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000001118 alkylidene group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000003005 anticarcinogenic agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
229940098166 bactrim Drugs 0.000 description 1
IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
YZJCDVRXBOPXSQ-UHFFFAOYSA-N benzyl pentanoate Chemical compound CCCCC(=O)OCC1=CC=CC=C1 YZJCDVRXBOPXSQ-UHFFFAOYSA-N 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
108091008034 costimulatory receptors Proteins 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
238000009795 derivation Methods 0.000 description 1
231100000020 developmental retardation Toxicity 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
238000007723 die pressing method Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
TZMFJUDUGYTVRY-UHFFFAOYSA-N ethyl methyl diketone Natural products CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
208000011323 eye infectious disease Diseases 0.000 description 1
208000024756 faint Diseases 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229930003949 flavanone Natural products 0.000 description 1
235000011981 flavanones Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
125000000457 gamma-lactone group Chemical group 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000004519 grease Substances 0.000 description 1
210000004884 grey matter Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
201000010284 hepatitis E Diseases 0.000 description 1
206010019847 hepatosplenomegaly Diseases 0.000 description 1
IGMNYECMUMZDDF-UHFFFAOYSA-N homogentisic acid Chemical compound OC(=O)CC1=CC(O)=CC=C1O IGMNYECMUMZDDF-UHFFFAOYSA-N 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000033065 inborn errors of immunity Diseases 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940041476 lactose 100 mg Drugs 0.000 description 1
201000005264 laryngeal carcinoma Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
239000002609 medium Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
WVWZECQNFWFVFW-UHFFFAOYSA-N methyl 2-methylbenzoate Chemical compound COC(=O)C1=CC=CC=C1C WVWZECQNFWFVFW-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940106051 methylcellulose (400 cps) Drugs 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
208000004141 microcephaly Diseases 0.000 description 1
239000003658 microfiber Substances 0.000 description 1
230000002969 morbid Effects 0.000 description 1
WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
235000007625 naringenin Nutrition 0.000 description 1
229940117954 naringenin Drugs 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
238000012856 packing Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
244000045947 parasite Species 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
229960004448 pentamidine Drugs 0.000 description 1
229960001476 pentoxifylline Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000000505 pernicious effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940100595 phenylacetaldehyde Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
208000028529 primary immunodeficiency disease Diseases 0.000 description 1
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
239000012744 reinforcing agent Substances 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
239000011435 rock Substances 0.000 description 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
238000006557 surface reaction Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Planar Illumination Modules (AREA)
Illuminated Signs And Luminous Advertising (AREA)
Securing Globes, Refractors, Reflectors Or The Like (AREA)

CNB931144442A 1992-10-01 1993-09-30 免疫强化剂及其生理上可接受的盐 Expired - Fee Related CN1213746C (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB929220715A GB9220715D0 (en)	1992-10-01	1992-10-01	Immunopotentiatory agent and physiologically acceptable salts thereof
GB9220715.8		1992-10-01
GB929226874A GB9226874D0 (en)	1992-12-23	1992-12-23	Immunopotentiatory agents and physiologically acceptable salts thereof
GB9226874.7		1992-12-23

Publications (2)

Publication Number	Publication Date
CN1091005A CN1091005A (zh)	1994-08-24
CN1213746C true CN1213746C (zh)	2005-08-10

Family

ID=26301715

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNB931144442A Expired - Fee Related CN1213746C (zh)	1992-10-01	1993-09-30	免疫强化剂及其生理上可接受的盐

Country Status (24)

Country	Link
US (1)	US5508310A (2)
EP (3)	EP0678298A3 (2)
JP (2)	JP3717950B2 (2)
KR (1)	KR100348775B1 (2)
CN (1)	CN1213746C (2)
AT (1)	ATE146075T1 (2)
AU (1)	AU676491B2 (2)
CA (1)	CA2124677C (2)
CZ (1)	CZ132794A3 (2)
DE (1)	DE69306545T2 (2)
DK (1)	DK0609606T3 (2)
ES (1)	ES2096215T3 (2)
GR (1)	GR3022541T3 (2)
HR (1)	HRP931243A2 (2)
HU (1)	HUT70482A (2)
IL (1)	IL107157A0 (2)
MX (1)	MX9306079A (2)
NZ (1)	NZ256110A (2)
RU (1)	RU94028670A (2)
SG (1)	SG48993A1 (2)
SI (1)	SI9300514A (2)
SK (1)	SK65294A3 (2)
WO (1)	WO1994007479A2 (2)
YU (1)	YU62793A (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3539795A (en) *	1994-08-25	1996-03-14	Medical University Of South Carolina	Methods of treating cold symptoms using pentoxifylline
GB9601544D0 (en) *	1996-01-26	1996-03-27	Smithkline Beecham Plc	Pharmaceuticals
BR9809149A (pt) *	1997-05-20	2000-08-01	Galenica Pharmaceuticals Inc	Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US6080725A (en) *	1997-05-20	2000-06-27	Galenica Pharmaceuticals, Inc.	Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ES2245805T3 (es) *	1997-10-03	2006-01-16	Galenica Pharmaceuticals, Inc.	Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
WO2000009075A2 (en)	1998-08-14	2000-02-24	Galenica Pharmaceuticals, Inc.	Chemically modified saponins and the use thereof as adjuvants
GB9818627D0 (en) *	1998-08-26	1998-10-21	Glaxo Group Ltd	Improvements in dva vaccination
US6939896B2 (en) *	1999-12-21	2005-09-06	Astrazeneca Ab	Cd45 inhibitors
JP2003518085A (ja) *	1999-12-21	2003-06-03	アストラゼネカアクチボラグ	Ｃｄ４５阻害剤
US7638496B2 (en)	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
AU2001245823A1 (en) *	2000-03-17	2001-10-03	Corixa Corporation	Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
PL211872B1 (pl)	2000-03-31	2012-07-31	Purdue Research Foundation	Kompozycja farmaceutyczna
AU2001251491A1 (en) *	2000-04-11	2001-10-23	Galenica Pharmaceuticals, Inc.	Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
CA2445826C (en) *	2001-05-02	2014-03-25	Purdue Research Foundation	Treatment and diagnosis of macrophage mediated disease
KR20040053136A (ko) *	2001-09-28	2004-06-23	펄듀 리서치 파운데이션	리간드-면역원 공액체를 이용한 치료 방법
US8246969B2 (en)	2001-11-16	2012-08-21	Skinmedica, Inc.	Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) *	2002-01-04	2003-08-21	Bryan Fuller	Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6911434B2 (en) *	2002-02-04	2005-06-28	Corixa Corporation	Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2004028470A2 (en) *	2002-09-27	2004-04-08	Martek Biosciences Corporation	Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
EP1622554A4 (en) *	2003-05-15	2008-01-02	Bioform Medical Inc	COMPOSITIONS CONTAINING A COMBINATION OF A PHARMACEUTICAL AGENT OR A COSMETIC AGENT AND AN OXY-GROUP-WEARING AROMATIC ALDEHYDE
KR20050118057A (ko) *	2004-04-24	2005-12-15	김상희	아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US7622128B2 (en) *	2005-12-13	2009-11-24	University Of Washington	Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US8168164B2 (en) *	2006-02-03	2012-05-01	Purdue Research Foundation	Targeted conjugates and radiation
JP5554713B2 (ja) *	2007-11-15	2014-07-23	エンドサイト，インク．	接合体を投与する方法
EP2661264B1 (en)	2011-01-07	2018-12-05	Allergan, Inc.	Melanin modification compositions and methods of use
MX383691B (es)	2015-03-06	2025-03-14	Beyondspring Pharmaceuticals Inc	Método de tratamiento de cáncer asociado con una mutación de ras.
US10155748B2 (en)	2015-07-13	2018-12-18	Beyondspring Pharmaceuticals, Inc.	Plinabulin compositions
WO2017139231A1 (en)	2016-02-08	2017-08-17	Beyondspring Pharmaceuticals, Inc.	Compositions containing tucaresol or its analogs
RU2760348C2 (ru)	2016-06-06	2021-11-24	Бейондспринг Фармасьютикалс, Инк.	Способ уменьшения нейтропении
JP2020503363A (ja)	2017-01-06	2020-01-30	ビヨンドスプリングファーマシューティカルズ，インコーポレイテッド	チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt)	2017-02-01	2020-03-31	Beyondspring Pharmaceuticals, Inc.	Método para reduzir neutropenia
KR20200112881A (ko)	2018-01-24	2020-10-05	비욘드스프링 파마수티컬스, 인코포레이티드.	플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CA3215047A1 (en)	2021-04-09	2022-10-13	Lan Huang	Therapeutic compositions and methods for treating tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS54126731A (en) *	1978-03-20	1979-10-02	Rikagaku Kenkyusho	Carcinostatic agent
JPS5545658A (en) *	1978-09-28	1980-03-31	Rikagaku Kenkyusho	Carcinostatic agent
JPS5569510A (en) *	1978-11-16	1980-05-26	Mitsubishi Chem Ind Ltd	Carcinostatic agent
IT1193786B (it) *	1980-12-18	1988-08-24	Wellcome Found	Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
LU85365A1 (de) *	1984-05-16	1986-01-29	Chimicasa Gmbh	Verfahren und praeparat zur stimulierung des immunsystems
DE3431236A1 (de) *	1984-08-24	1986-02-27	Carnivora-Deutschland GmbH, 7109 Jagsthausen	Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
DE3528709A1 (de) *	1985-08-09	1987-02-19	Schleicher Peter	Mundpflegemittel
JPS63264409A (ja) *	1988-01-13	1988-11-01	Rikagaku Kenkyusho	制癌剤
JPH03254007A (ja) *	1990-03-01	1991-11-13	Tir Syst Ltd	非吸収性で且つ透過率が可変のカバーを有した照明装置
GB9018061D0 (en) *	1990-08-17	1990-10-03	Wellcome Found	Compositions for vaccines
EP0499015A1 (en) *	1991-02-15	1992-08-19	Fockerman, Jasmine	Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents

1993
- 1993-09-17 DE DE69306545T patent/DE69306545T2/de not_active Expired - Lifetime
- 1993-09-17 DK DK93307373.6T patent/DK0609606T3/da active
- 1993-09-17 ES ES93307373T patent/ES2096215T3/es not_active Expired - Lifetime
- 1993-09-17 AT AT93307373T patent/ATE146075T1/de not_active IP Right Cessation
- 1993-09-17 EP EP95110267A patent/EP0678298A3/en not_active Withdrawn
- 1993-09-17 SG SG1996004981A patent/SG48993A1/en unknown
- 1993-09-17 EP EP93307373A patent/EP0609606B1/en not_active Expired - Lifetime
- 1993-09-29 IL IL107157A patent/IL107157A0/xx unknown
- 1993-09-30 KR KR1019940701840A patent/KR100348775B1/ko not_active Expired - Fee Related
- 1993-09-30 HR HR931243A patent/HRP931243A2/hr not_active Application Discontinuation
- 1993-09-30 RU RU94028670/14A patent/RU94028670A/ru unknown
- 1993-09-30 JP JP27730093A patent/JP3717950B2/ja not_active Expired - Fee Related
- 1993-09-30 MX MX9306079A patent/MX9306079A/es unknown
- 1993-09-30 NZ NZ256110A patent/NZ256110A/en unknown
- 1993-09-30 CN CNB931144442A patent/CN1213746C/zh not_active Expired - Fee Related
- 1993-09-30 WO PCT/GB1993/002039 patent/WO1994007479A2/en not_active Ceased
- 1993-09-30 EP EP93921034A patent/EP0614357A1/en not_active Withdrawn
- 1993-09-30 SK SK652-94A patent/SK65294A3/sk unknown
- 1993-09-30 JP JP6508846A patent/JPH07504204A/ja not_active Withdrawn
- 1993-09-30 HU HU9401631A patent/HUT70482A/hu unknown
- 1993-09-30 YU YU62793A patent/YU62793A/sh unknown
- 1993-09-30 CZ CZ941327A patent/CZ132794A3/cs unknown
- 1993-09-30 AU AU48311/93A patent/AU676491B2/en not_active Ceased
- 1993-09-30 SI SI9300514A patent/SI9300514A/sl unknown
- 1993-09-30 CA CA002124677A patent/CA2124677C/en not_active Expired - Fee Related
1995
- 1995-05-19 US US08/446,080 patent/US5508310A/en not_active Expired - Fee Related
1997
- 1997-02-12 GR GR970400229T patent/GR3022541T3/el unknown

Also Published As

Publication number	Publication date
GR3022541T3 (en)	1997-05-31
JP3717950B2 (ja)	2005-11-16
DE69306545D1 (de)	1997-01-23
CA2124677A1 (en)	1994-04-14
ES2096215T3 (es)	1997-03-01
US5508310A (en)	1996-04-16
NZ256110A (en)	1997-07-27
DE69306545T2 (de)	1997-04-03
EP0614357A1 (en)	1994-09-14
RU94028670A (ru)	1996-05-20
WO1994007479A3 (en)	1994-07-21
EP0678298A3 (en)	1996-05-29
CZ132794A3 (en)	1995-02-15
DK0609606T3 (2)	1997-03-17
MX9306079A (es)	1994-06-30
AU4831193A (en)	1994-04-26
YU62793A (sh)	1998-05-15
SG48993A1 (en)	1998-05-18
WO1994007479A2 (en)	1994-04-14
EP0678298A2 (en)	1995-10-25
JPH072660A (ja)	1995-01-06
HRP931243A2 (en)	1995-12-31
AU676491B2 (en)	1997-03-13
IL107157A0 (en)	1993-12-28
EP0609606B1 (en)	1996-12-11
HUT70482A (en)	1995-10-30
EP0609606A1 (en)	1994-08-10
CN1091005A (zh)	1994-08-24
SK65294A3 (en)	1995-03-08
CA2124677C (en)	2008-09-09
HU9401631D0 (en)	1994-08-29
JPH07504204A (ja)	1995-05-11
SI9300514A (en)	1994-06-30
KR100348775B1 (ko)	2003-02-11
ATE146075T1 (de)	1996-12-15

Legal Events

Date	Code	Title	Description
1994-08-24	C06	Publication
1994-08-24	PB01	Publication
1996-02-07	C10	Entry into substantive examination
1996-02-07	SE01	Entry into force of request for substantive examination
2005-08-10	C14	Grant of patent or utility model
2005-08-10	GR01	Patent grant
2011-12-14	C17	Cessation of patent right
2011-12-14	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20050810 Termination date: 20100930

Publication	Publication Date	Title
CN1213746C (zh)	2005-08-10	免疫强化剂及其生理上可接受的盐
CN1541105A (zh)	2004-10-27	用维生素b12和干扰素联合治疗病毒性、增殖性和炎性疾病的方法
CN1494898A (zh)	2004-05-12	含有胶体二氧化硅的缬无环鸟苷片剂
CN1046727C (zh)	1999-11-24	Hiv蛋白酶抑制剂
CN1278727A (zh)	2001-01-03	单胺氧化酶抑制剂和h5－ht1B拮抗剂或部分激动剂的组合
CN1080853A (zh)	1994-01-19	N-(膦酰基乙酰基)-l-天冬氨酸组合物及其作为广谱抗病毒的使用方法
CN1211089C (zh)	2005-07-20	尿苷磷酸化酶抑制剂的制药应用及含其的组合物
CN1976723A (zh)	2007-06-06	感染性疾病的治疗
CN1605335A (zh)	2005-04-13	含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
CN1826124A (zh)	2006-08-30	用于治疗骨转移瘤、肿瘤生长和肿瘤诱导的骨丢失的组织蛋白酶k抑制剂和二膦酸盐/酯的组合
CN1283239C (zh)	2006-11-08	作为杀锥虫剂的1－氨基－烷基环己烷类
US20230078120A1 (en)	2023-03-16	Methods for Treating Coronavirus Infections
CN1636013A (zh)	2005-07-06	可编码hiv辅助蛋白的dna疫苗
CN1714842A (zh)	2006-01-04	一种疏肝利胆和清热解毒的中药组合物及其制法
CN1572298A (zh)	2005-02-02	含有阿比朵尔的复方制剂
CN1323717C (zh)	2007-07-04	重组人干扰素α1b口含片及其制备方法
RU2825648C1 (ru)	2024-08-28	Способы лечения коронавирусных инфекций
CN1093906A (zh)	1994-10-26	抗病毒剂
CN1198840C (zh)	2005-04-27	人类乳头瘤病毒11l1－e7重组蛋白及其应用
CN1608056A (zh)	2005-04-20	羧酸衍生物化合物和包含这种化合物作为活性成分的药剂
CN101056673A (zh)	2007-10-17	4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
CN1709238A (zh)	2005-12-21	一种具有保肝作用的静脉注射用粉针及其制备与质量控制方法
WO2025119151A1 (zh)	2025-06-12	Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用
CN1628852A (zh)	2005-06-22	一种抗实体肿瘤药物组合物
EP2517709A1 (en)	2012-10-31	Medical and pharmaceutical use of 2', 2-bis-thiazole non-nucleoside compounds as hepatitis c virus inhibitor